

EuroEyes

EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司
(Stock Code: 1846.HK)

EuroEyes Secures Four-year Medical Supplier Agreement with Carl Zeiss AG, Further Optimising Procurement Costs and Strengthening Ties Between the Two Companies

Hong Kong, 9 September 2022 – EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846), a leading global vision correction service provider, today announced it has signed a four-year medical equipment supplier agreement with Carl Zeiss AG, effective 1 July 2022. This will ensure the stable supply of refractive surgery goods and equipment for the Group, while at the same time enable EuroEyes to further optimise its cost control measures.



PHOTO CAPTION: *Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes (right), and Andrew Chang, Head of Global Sales Ophthalmic Devices and President of Carl Zeiss Meditec USA Inc., signed agreement extending Carl Zeiss AG as a medical supplier to EuroEyes for the next four years.*

A signing ceremony was held at EuroEyes headquarters in Hamburg, Germany on 2 September. The agreement will allow the Group to secure the most advanced and relevant equipment from Carl Zeiss, including lenses, laser systems, and also embark on scientific collaborations that will enable EuroEyes to equip its clinics globally with state-of-the-art technologies.

Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes, said: “We are pleased to be strengthening our years of partnership with Carl Zeiss. Our renewed agreement will not only ensure the stability of our medical supplies, but also foster closer collaboration to develop innovative refractive surgery equipment for the treatment of presbyopia.

“In addition, EuroEyes will be able to secure stable purchase price on goods and equipment from Carl Zeiss in the coming years, which will help us weather the rising inflationary environment. This will enable us to optimise our cost control measures and maintain a healthy cost structure that could benefit our patients and shareholders.”

“Over the years, our partnership with Carl Zeiss has led to technological breakthroughs that enabled us to treat more than 600,000 patients globally. Our success has earned us multiple accolades, including the largest implanter of Zeiss AT LISA® trifocal intraocular lens (IOL) worldwide for seven consecutive years,” **Dr. Jørgensen added.**

###

About EuroEyes International Eye Clinic Limited (1846.HK)

EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark, the PRC and the United Kingdom. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit www.euroeyes.hk.

For more information, please contact:

Hume Brophy Communications – Jane Hung / Connie Chan, euroeyeshk@humbrophy.com